Categories: HealthDay

FDA OKs 1st Biosimilar to Prevent Chemo-Related Infections

TUESDAY, June 5, 2018 (HealthDay News) — The first biosimilar drug to Neulasta has been approved by the U.S. Food and Drug Administration. Fulphila (pegfilgrastim) is approved for patients with non-myeloid cancer who are receiving myelosuppressive chemotherapy and have symptoms of febrile neutropenia.

A biosimilar drug, generally derived from a living organism, is approved based on clinical evidence that it is “highly similar” to a product that’s already approved by the FDA, and that there are “no clinically meaningful differences” in safety, purity and potency, the agency said.

The most common side effects of Fulphila are pain in the bones, arms and legs. Less common but more serious adverse reactions include the possibility of spleen rupture, severe respiratory problems and allergic reactions, glomerulonephritis, leukocytosis, tumor growth, and “fatal sickle cell crises,” the FDA said.

“We want to make sure that the pathway for developing biosimilar versions of approved biologics is efficient and effective, so that patients benefit from [price] competition to existing biologics once lawful intellectual property has lapsed on these products,” FDA Commissioner Scott Gottlieb, M.D., said in a statement.

Fulphila is produced by Mylan, with U.S. headquarters in Canonsburg, Penn.

More Information

Copyright © 2018 HealthDay. All rights reserved.

Physicians Weekly

Share
Published by
Physicians Weekly

Recent Posts

Trends in Merkel Cell Carcinoma

Study results suggest that the incidence of Merkel cell carcinoma (MCC) appears to be increasing dramatically in the United States.…

7 mins ago

China’s Guangdong province bans transport of live hogs as swine fever spreads

BEIJING (Reuters) - China's southern Guangdong province on Tuesday banned the transport of live hogs to other parts of the…

2 hours ago

AbbVie rheumatoid arthritis drug succeeds in late stage trial

NEW YORK (Reuters) - AbbVie Inc on Tuesday said its experimental rheumatoid arthritis (RA) treatment showed significant improvement in physical…

2 hours ago

Vaccine confidence low in Europe, raising disease outbreak risk

By Kate Kelland LONDON (Reuters) - Low levels of public confidence in vaccines in the European Union are pushing immunization…

2 hours ago

#PWChat: ICU Safety

Join us Thursday, October 25 at 9:00pm ET for a live, interactive tweetchat on ICU safety with Kelly Cawcutt, MD,…

3 hours ago

Siemens Healthineers partners with Healthy.io for smartphone-based urine testing

BERLIN (Reuters) - Siemens Healthineers has teamed up with Israeli start-up Healthy.io to allow patients to test their urine at…

4 hours ago
avtomaticheskij-poliv.com.ua

красивые детские платья

www.niko-centre.kiev.ua